| Dr Andrea Rose Mazzoni, MD | |
|
1240 Huffman Mill Rd, Burlington, NC 27215-8700 | |
| (336) 538-7179 | |
| Not Available |
| Full Name | Dr Andrea Rose Mazzoni |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 11 Years |
| Location | 1240 Huffman Mill Rd, Burlington, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093158966 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 2017-01468 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alamance Regional Medical Center | Burlington, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| American Anesthesiology Of North Carolina Pllc | 2961316450 | 383 |
News Archive
SuperGen, Inc. (NASDAQ:SUPG) and GlaxoSmithKline (NYSE:GSK) have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets.
The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated.
A new study identifies six main patient-reported barriers to receiving quality end-of-life (EOL) care among ethnic minority populations. The biggest barrier is lack of sufficient financial resources and insurance, according to the article published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
› Verified 1 days ago
| Entity Name | American Anesthesiology Of North Carolina Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033412267 PECOS PAC ID: 2961316450 Enrollment ID: O20031118000860 |
News Archive
SuperGen, Inc. (NASDAQ:SUPG) and GlaxoSmithKline (NYSE:GSK) have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets.
The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated.
A new study identifies six main patient-reported barriers to receiving quality end-of-life (EOL) care among ethnic minority populations. The biggest barrier is lack of sufficient financial resources and insurance, according to the article published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
› Verified 1 days ago
| Entity Name | Regional Anesthesia, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952486946 PECOS PAC ID: 3779681408 Enrollment ID: O20070604000698 |
News Archive
SuperGen, Inc. (NASDAQ:SUPG) and GlaxoSmithKline (NYSE:GSK) have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets.
The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated.
A new study identifies six main patient-reported barriers to receiving quality end-of-life (EOL) care among ethnic minority populations. The biggest barrier is lack of sufficient financial resources and insurance, according to the article published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
› Verified 1 days ago
| Entity Name | The Moses H Cone Memorial Hospital Operating Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013265909 PECOS PAC ID: 6204744600 Enrollment ID: O20121003000518 |
News Archive
SuperGen, Inc. (NASDAQ:SUPG) and GlaxoSmithKline (NYSE:GSK) have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets.
The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated.
A new study identifies six main patient-reported barriers to receiving quality end-of-life (EOL) care among ethnic minority populations. The biggest barrier is lack of sufficient financial resources and insurance, according to the article published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrea Rose Mazzoni, MD 3100 Spring Forest Rd Ste 130, Raleigh, NC 27616-2880 Ph: (919) 882-0774 | Dr Andrea Rose Mazzoni, MD 1240 Huffman Mill Rd, Burlington, NC 27215-8700 Ph: (336) 538-7179 |
News Archive
SuperGen, Inc. (NASDAQ:SUPG) and GlaxoSmithKline (NYSE:GSK) have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets.
The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated.
A new study identifies six main patient-reported barriers to receiving quality end-of-life (EOL) care among ethnic minority populations. The biggest barrier is lack of sufficient financial resources and insurance, according to the article published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
› Verified 1 days ago
Mark Randall Noles, CRNA Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1240 Huffman Mill Rd, Burlington, NC 27215 Phone: 501-590-4790 | |
Dr. Andrew Meyer, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1236 Huffman Mill Rd, Suite 2000, Burlington, NC 27215 Phone: 336-585-1770 | |
Deitra Letrice Williams-toone, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Huffman Mill Rd, Burlington, NC 27215 Phone: 336-584-5544 Fax: 336-584-4438 | |
Dr. Farooque S.a. Khan, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2961 Crouse Lane, Suite D, Burlington, NC 27215 Phone: 336-584-7050 Fax: 336-584-7066 | |
Dr. Paul J Carroll, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1236 Huffman Mill Rd, Ste 2000, Burlington, NC 27215 Phone: 336-585-1770 | |
Joseph King Piscitello, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1240 Huffman Mill Rd, Burlington, NC 27215 Phone: 336-585-1770 Fax: 336-585-1771 |